Novartis receives European Commission approval for sixth indication of Lucentis
Novartis receives European Commission approval for sixth indication of Lucentis
About this item
Full title
Novartis receives European Commission approval for sixth indication of Lucentis
Publisher
London: Normans Media Ltd
Journal title
M2 Pharma, 2016
Language
English
Formats
Publication information
Publisher
London: Normans Media Ltd
Subjects
More information
Scope and Contents
Contents
M2PHARMA-December 9, 2016-Novartis receives European Commission approval for sixth indication of Lucentis (C)2016 M2 COMMUNICATIONS http://www.m2.com Novartis, a Swiss multinational pharmaceutical company, has received approval for the sixth indication of its Lucentis (ranibizumab) drug from the Europ...
Alternative Titles
Full title
Novartis receives European Commission approval for sixth indication of Lucentis
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_wirefeeds_1847389420
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_wirefeeds_1847389420
How to access this item
Log in as a Library member
